Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
The latest drug development news and highlights from our FDA Performance Tracker.
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.